The drug-delivery technology that enables Bydureon to be dosed so infrequently comes from Alkermes ( ALKS), which will receive royalties on sales of the drug when approved. Bydureon and Novo Nordisk's ( NVO) recently approved Victoza belong to the GLP-1 class of injectable diabetes drugs intended to control blood sugar in Type 2 diabetes medicines. Victoza requires a once-daily injection. Amylin shares closed Friday at $20.26; Alkermes shares closed at $12.21. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.